Type 1 diabetes mellitus and physical activity, the possibilities of using insulin degludec: analysis of clinical cases

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Regular physical activity is an integral part of the life of patients with type 1 diabetes mellitus (DM1) due to their young age. Regular aerobic physical activity is associated with improved overall well-being and is a method of preventing cardiovascular diseases. An increased risk of nocturnal hypoglycemia after physical activity is a factor limiting physical activity, especially in young patients and children. Insulin degludec is an analogue of long-acting basal insulin (with a duration of action of more than 42 hours), which has a low variability of action. The ADREM study, conducted using continuous glucose monitoring systems, demonstrated that afternoon aerobic exercise in patients with DM1 treated with insulin degludec did not affect the risk of subsequent nocturnal hypoglycemia. This article reviews a case series of patients with DM1 treated with insulin degludec and regularly engaged in physical activity.

全文:

受限制的访问

作者简介

Olga Elsukova

Kirov State Medical University; Kirov Clinical Hospital No. 7 named after V.I. Yurlova

编辑信件的主要联系方式.
Email: oselsukova@mail.ru
ORCID iD: 0000-0002-2341-9491

Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy, Head of the Endocrinology Department, Regional Endocrinology Center

俄罗斯联邦, Kirov; Kirov

参考

  1. Chimen M., Kennedy A., Nirantharakumar K., et al. Whatarethehealthbenefits ofphysical activity in type 1 diabetes mellitus? A literature review. Diabetologia. 2012;55(3):542–51. doi: 10.1007/s00125-011-2403-2.
  2. Metcalf K.M., Singhvi A., Tsalikian E., et al. Effects of moderate-to-vigorous intensity physical activity on overnight and next-day hypoglycemia in active adolescents with type 1 diabetes. Diab Care. 2014;37(5):1272–8. doi: 10.2337/dc13 1973.
  3. McMahon S.K., Ferreira L.D., Ratnam N., et al. Glucose requirements to maintain euglycemia after moderate-intensity after noon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J Clin Endocrinol Metab. 2007;92(3):963–8. doi: 10.1210/jc.2006-2263.
  4. Gomez A.M., Gomez.C., Aschner P., et al. Effects of perform ing morning versus afternoon exercise on glycemic control and hypoglycemia frequency in type 1 diabetes patients on sensor augmented insulin pump therapy. J Diabetes Sci Technol. 2015;9(3):619–24. doi: 10.1177/1932296814566233.
  5. Graveling A.J., Frier B.M. The risks of nocturnal hypoglycaemia in insulin-treated diabetes. Diabetes Res Clin Pract. 2017133:30–9. doi: 10.1016/j.diabres.2017.08.012.
  6. Campbell M.D., Walker M., Bracken R. Insulintherapy and dietary adjustments to normalize glycemia and prevent noctur nal hypoglycemia after evening exercise in type 1 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2015;3(1):e000085. doi: 10.1136/bmjdrc-2015-000085.
  7. Heise T., Hermanski L., Nosek L., et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diab Obes Metab. 2012;14(9):859–64. doi: 10.1111/j.1463-1326.2012.01627.x.
  8. Drenthen L.C.A., Ajie M., Abbink E.J., et al. No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study. Diabetologia. 2023;66(6):1035–44. doi: 10.1007/s00125-023-05893-9.
  9. Wysham C.., Bhargava A, Chaykin L., et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes. JAMA. 2017;318(1):45. doi: 10.1001/jama.2017.7117.
  10. Liu W., Yang X., Huang J. Efficacy and safety of insulin degludec versus insulin glargine: A systematic review and meta-analysis of fifteen clinical trials. Int J Endocrinol. 2018;2018(2):1–10. doi: 10.1155/2018/8726046.
  11. Ratner R.E., Gough S.C.L., Mathieu C., et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diab Obes Metab. 2013;15(2):175–84. doi: 10.1111/dom.12032.

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure. 1. Data of monitoring of patient Sh. during therapy (daily training for 2 hours in the morning): insulin degludec 15 U, ultra-fast-acting insulin aspart according to BU

下载 (294KB)
索引源数据
3. Figure. 2. Data of monitoring of patient Sh. during therapy (daily training for 2 hours in the morning): insulin degludec 15 U, ultra-fast-acting insulin aspart according to BU

下载 (364KB)
索引源数据
4. Figure. 3. Data of monitoring of patient Sh. during therapy: (daily training for 2 hours in the morning): insulin degludec 15 U, ultra-fast-acting insulin aspart according to BU

下载 (86KB)
索引源数据
5. Figure. 4. Data of monitoring of patient Sh. during therapy: (daily training for 2 hours in the morning): insulin degludec 15 U, ultra-fast-acting insulin aspart according to BU

下载 (174KB)
索引源数据
6. Figure. 5. Data of monitoring of patient K. during therapy (daily training in the evening 4 days a week for 2 hours): insulin degludec 17 U, ultra-fast-acting insulin aspart according to BU

下载 (290KB)
索引源数据
7. Figure. 6. Data of monitoring of patient K. during therapy (daily training in the evening 4 days a week for 2 hours): insulin degludec 17 U, ultra-fast-acting insulin aspart according to BU

下载 (345KB)
索引源数据
8. Figure. 7. Data of monitoring of patient K. during therapy (daily training in the evening 4 days a week for 2 hours): insulin degludec 17 U, ultra-fast-acting insulin aspart according to BU

下载 (359KB)
索引源数据

版权所有 © Bionika Media, 2025